About KaryoLogic
KaryoLogic is a Healthcare company based in Durham (United States) founded in 2008, and was acquired by Clean Cells in April 2025. It operates as a company offers karyotyping and digital PCR services for human, mouse, and rare species, stem cell and cancer cell lines. KaryoLogic offers products and services including Human Stem Cell Karyotyping and Digital PCR, Human Non-Stem Cell Karyotyping, Non-Human Species Karyotyping, and Fluorescence In Situ Hybridization. Its focus areas include Biopharma Outsourcing, CRO and Diversified. Its legal entity is KaryoLogic, Inc. Its competitors include Charles River Laboratories, LabCorp, Cytel, Precision Medicine Group and Veeda Clinical Research and 5 more; 5 of its 10 listed competitors have raised funding.
Company details
KaryoLogic offers karyotyping services for human, mouse, and rare species, stem cell and cancer cell lines, as well as digital PCR services for human stem cells. They accept cell samples shipped from around the globe to their North Carolina USA location for high quality karyotyping services. KaryoLogic has also partnered with other biotech companies to improve their services.
- Headquarters Durham, United States
- Stage Acquired
- SectorsHealthcare
- Website karyologic.com
- Acquired by Clean Cells (Apr 2025)
- Legal Name Karyologic, Inc.
- Investors
- Acquired byClean Cells
(Apr 2025)
Products & Services of KaryoLogic
KaryoLogic offers a comprehensive portfolio of products and services, including Human Stem Cell Karyotyping and Digital PCR, Human Non-Stem Cell Karyotyping, Non-Human Species Karyotyping, and Fluorescence In Situ Hybridization.
Analyzes chromosomes in human stem cells for research integrity
Performs chromosome analysis on human non-stem cells
Offers karyotyping for animal and other species
Detects specific DNA sequences in chromosomes
Investors in KaryoLogic
KaryoLogic has secured backing from 1 investor. Prominent investors backing the company include Clean Cells.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Offers cell banking and virus banking services | 2000 | clean-cells.com | Bouffere, France |
Investor details for KaryoLogic
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of KaryoLogic
2 dated milestones of KaryoLogic across 17 years, from founding to its latest funding, stage changes and deals.
- Founded KaryoLogic is founded.
- Exit Acquired by Clean Cells.
Competitors of KaryoLogic
KaryoLogic has 10 listed competitors in our database, 5 of them funded. They include Charles River Laboratories, LabCorp, Cytel, Precision Medicine Group and Veeda Clinical Research, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| criver.com | 1947 | Wilmington, United States | – | 21,400 | Provider of drug discovery and preclinical development services | |
| labcorp.com | 1969 | Burlington, United States | – | 9,321 | Provider of laboratory tests for physicians | |
| cytel.com | 1987 | Cambridge, United States | $2M | 509 | Data analysis and statistical solutions are provided for life sciences. | |
| precisionmedicinegrp.com | 2012 | Bethesda, United States | $257.21M | 2,151 | Provider of clinical research, development, and commercialization services for life sciences | |
| veedacr.com | 2004 | Ahmedabad, India | – | – | Drug development services encompassing clinical trials, bioanalytical support, and real-world evidence in healthcare. | |
| precisionformedicine.com | 2013 | Bethesda, United States | $150M | – | Company offering specialised R&D and clinical development services for the development of precision medicine based drugs and devices | |
| covance.com | 1996 | Princeton, United States | – | – | CRO offering comprehensive drug development solutions from drug discovery to life cycle management | |
| qps.com | 1995 | Newark, United States | – | – | Contract research organisation offering drug discovery, preclinical and clinical development services | |
| frontagelab.com | 2001 | Exton, United States | $10.24M | – | Early drug development services are provided for pharma firms. | |
| canopybiosciences.com | 2016 | St. Louis, United States | $4.48M | – | Cell line engineering services are offered via CRISPR-Cas9 technology. |
Detailed competitors of KaryoLogic
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of KaryoLogic
Websites that share an audience with KaryoLogic (karyologic.com).
Websites whose visitors overlap most with KaryoLogic. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| clgenetics.com | 100% | 1.8K | #9,820,792 | View details |
Top companies in Biopharma Outsourcing & Drug Delivery
10 companies that operate in the same segment as KaryoLogic (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Karyologic
Complete news archive for KaryoLogic
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about KaryoLogic
KaryoLogic was founded in 2008.
KaryoLogic is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
KaryoLogic offers karyotyping services for human, mouse, and rare species, stem cell and cancer cell lines, as well as digital PCR services for human stem cells. They accept cell samples shipped from around the globe to their North Carolina USA location for high quality karyotyping services. KaryoLogic has also partnered with other biotech companies to improve their services.
KaryoLogic's top competitors include LabCorp, Charles River Laboratories and Cytel.
KaryoLogic offers Human Stem Cell Karyotyping and Digital PCR, Human Non-Stem Cell Karyotyping, Non-Human Species Karyotyping, and Fluorescence In Situ Hybridization.
KaryoLogic has 1 investor. Key investors include Clean Cells.
KaryoLogic operates through Karyologic, Inc..
Yes. KaryoLogic was acquired by Clean Cells in April 2025.